Primo Biotechnology is a leader in Radionuclide Drug Conjugates (RDC), offering a comprehensive ecosystem—from isotope supply and radiopharmaceutical development to automated synthesis and clinical support. We are dedicated to advancing Radioligand Theranostics (RLT), seamlessly integrating diagnosis and therapy. 

Our radiopharmaceutical pipeline features advanced diagnostic tracers for prostate, breast, and brain cancers, among others. Beyond our professional R&D team and evidence-based clinical support, we leverage our CRO/CDMO capabilities to offer essential technical consulting and clinical trial support for nuclear medicine development.